NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Abvance Therapeutics

Abvance Therapeutics

Private
Reno, NevadaHealthcare & Life Scienceshttps://abvancetherapeutics.com/

Last Round

Seed

Jun 24, 2025

Total Funding Raised

$3.9M

Company Overview

Abvance Therapeutics is a biotechnology company developing glucagon-based therapies designed to prevent hypoglycemia and improve glucose management for diabetes patients.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

biopharmaceuticaldiabetes managementinsulin therapyhypoglycemiadrug developmentcombination therapypeptide drugglycemic controlbiotech startuppreclinical researchdiabetes techdrug discovery

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Abvance Therapeutics Comparables

Compare Abvance Therapeutics with similar companies based on industry and business-model similarity.

Abvance Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Zucara Therapeutics Inc.
78%
Sensulin
78%
Zealand Pharma
71%

Abvance Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
SeedJun 24, 2025
DebtSep 10, 2024

Key People

Founding team and executive leadership

Edward Raskin

Chief Executive Officer

Executive Team

Abvance Therapeutics Investors

Notable investors and investment history

Abvance Therapeutics investors
InvestorRounds
Helmsley Charitable TrustDebt
Zubi CapitalSeed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 24, 2025

    Seed round led by Zubi Capital.

Abvance Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Abvance Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Abvance Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersReno, Nevada
Employee Range9
Year Founded2016
Last FundingJun 24, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.